Concepedia

Giovanna Speranza

GS

18

Publications

6K

Citations

17

H-Index

2011

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

German Center for Lung Research

Westmead Hospital

The University of Sydney

University of California, Los Angeles

Giovanna Speranza is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and radiation oncology.

Top concepts

Publications per year

2011–2023

18

Publications

18

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza et al. · Journal of Clinical Oncology · 2020 · 1.1K citations · Full text

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

Marina Chiara Garassino, Shirish M. Gadgeel, Giovanna Speranza et al. · Journal of Clinical Oncology · 2023 · 549 citations · Full text

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Shivaani Kummar, Alice P. Chen, Jiuping Ji et al. · Cancer Research · 2011 · 252 citations

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Marina Chiara Garassino, Shirish M. Gadgeel, Emilio Esteban et al. · The Lancet Oncology · 2020 · 207 citations

, , +8

Rows per page

1–5 of 18